Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)52 enrolled

Overview

Background: The flu is a common viral infection that can be deadly for certain people. Vaccines against flu have been developed to teach the body to prevent or fight the infection. A new vaccine may help the body to make an immune response to H1 flu, a flu strain that infects humans. Objective: To test the safety and effectiveness of the H1 Stabilized Stem Ferritin vaccine (VRC-FLUNPF099-00-VP). Eligibility: Healthy people ages 18-70 years old who got at least 1 licensed flu vaccine since January 1, 2014. Design: Participants received 1 or 2 vaccinations by injections (shots) in the upper arm muscle over 4 months. Participants received a thermometer and recorded their temperature and symptoms every day a diary card for 7 days after each injection. The injection site was checked for redness, swelling, or bruising. Participants had 9-11 follow-up visits over 12-15 months. At follow-up visits, participants had blood drawn and were checked for health changes or problems. Participants who reported influenza-like illness had nose and throat swabs for evaluation of viral infection. Some participants had apheresis. A needle was placed into a vein in both arms. Blood was removed through a needle in the vein of one arm. A machine removed the white blood cells and then the rest of the blood was returned to the participant through a needle in the other arm. A separate consent was provided to participants for genetic testing on their samples.

Study Design: This was a Phase I, open-label, dose escalation study to evaluate the dose, safety, tolerability, and immunogenicity of VRC-FLUNPF099-00-VP in two regimens. The hypotheses were that the vaccine is safe and tolerable and will elicit an immune response. The primary objective was to evaluate the safety and tolerability of the investigational vaccine in healthy adults. Secondary objectives were related to immunogenicity of the investigational vaccine and dosing regimen. Study Products: The investigational vaccine, VRC-FLUNPF099-00-VP (H1ssF\_3928), was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID) and is composed of Helicobacter pylori non-heme ferritin assembled with influenza virus H1 haemagglutinin (HA) insert to form a nanoparticle displaying eight HA stabilized stem trimers from A/New Caledonia/20/1999 (H1N1) influenza. The vaccine was supplied in single-use vials at a concentration of 180 mcg/mL. H1ssF\_3928 was administered intramuscularly (IM) in the deltoid muscle via needle and syringe. Participants: Healthy adults between the ages of 18-70 years, inclusive. Study Plan: The study evaluated the safety, tolerability and immunogenicity of 1 or 2 doses of the H1ssF\_3928 vaccine in a dose-escalation design. In Group 1, five participants received a single low dose (20 mcg) of H1ssF\_3928 on Day 0. For Group 1, the protocol required 1 vaccination visit, about 9 follow-up visits, and a telephone contact after vaccination. Once the low dose was assessed as safe and well tolerated, enrollment began for Group 2A. Groups 2A, 2B, 2C, and 2D were stratified by age as shown in the vaccination schema below. In Group 2A, participants received a higher dose (60 mcg) of H1ssF\_3928 on Day 0. Once this higher dose was assessed as safe and well tolerated, participants in Group 2A received a second vaccination at Week 16 and enrollment began for Groups 2B, 2C, and 2D. For Groups 2A, 2B, 2C, and 2D, the protocol required 2 vaccination visits, about 11 follow-up visits, and a telephone contact after each vaccination. Group 2A completed the product administration schedule per protocol. While most participants in Groups 2B-2D completed the second dose administration per protocol, one participant was not able to receive the second dose due to moving out of the area and 11 participants were not able to receive their second dose due to the COVID-19 pandemic. For all groups, solicited reactogenicity was evaluated using a 7-day diary card. Assessment of vaccine safety included clinical observation and monitoring of hematological and chemical parameters at clinical visits throughout the study. VRC 321 Vaccination Schema: Group: 1; Age Cohort: 18-40; Participants: 5; Day 0: 20 mcg Group: 2A; Age Cohort: 18-40; Participants: 12; Day 0: 60 mcg; Week 16: 60 mcg Group: 2B; Age Cohort: 41-49; Participants: 12; Day 0: 60 mcg; Week 16: 60 mcg Group: 2C; Age Cohort: 50-59; Participants: 12; Day 0: 60 mcg; Week 16: 60 mcg Group: 2D; Age Cohort: 60-70; Participants: 11\*; Day 0: 60 mcg; Week 16: 60 mcg Total: 52\* \*Recruitment for the final open group, Group 2D, was ongoing to meet the accrual target of 53 participants. However, due to the COVID-19 pandemic, enrollment was discontinued with a total of 52 participants enrolled. Study Duration: Group 1: Participants were evaluated for 52 weeks following the vaccine administration and through an influenza season. Groups 2A, 2B, 2C, 2D: Participants were evaluated for 52 weeks following the last vaccine administration and through an influenza season.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

INCLUSION CRITERIA: 1. Healthy adults between the ages of 18-70 years inclusive 2. Based on history and examination, in good general health and without history of any of the conditions listed in the exclusion criteria 3. Received at least one licensed influenza vaccine from 2014 to the present 4. Able and willing to complete the informed consent process 5. If enrolled in Group 1: Available for clinic visits for 52 weeks after enrollment and through an influenza season 6. If enrolled in Group 2A, 2B, 2C, or 2D: Available for clinic visits for 68 weeks after enrollment and through an influenza season 7. Willing to have blood samples collected, stored indefinitely, and used for research purposes 8. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process 9. Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) less than or equal to 40 within the 28 days before enrollment Laboratory Criteria within 28 days before enrollment 10. White blood cells (WBC) and differential either within institutional normal range or accompanied by the site Principal Investigator (PI) or designee approval 11. Total lymphocyte count greater than or equal to 800 cells/mm\^3 12. Platelets = 125,000 - 500,000/mm3 13. Hemoglobin within institutional normal range 14. Serum iron either within institutional normal range or accompanied by the site PI or designee approval 15. Serum ferritin within institutional normal range or accompanied by the site PI or designee approval 16. Alanine aminotransferase (ALT) less than or equal to 1.25 x institutional upper limit of normal (ULN) 17. Aspartate aminotransferase (AST) less than or equal to 1.25 x institutional ULN 18. Alkaline phosphatase (ALP) \<1.1 x institutional ULN 19. Total bilirubin within institutional normal range 20. Serum creatinine less than or equal to 1.1 x institutional ULN 21. Negative for HIV infection by an FDA-approved method of detection Criteria applicable to women of childbearing potential: 22. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on the day of enrollment 23. Agreed to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study EXCLUSION CRITERIA: 1. Breast-feeding or planning to become pregnant during the study. Participant has received any of the following substances: 2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment 3. Blood products within 16 weeks prior to enrollment 4. Live attenuated vaccines within 4 weeks prior to enrollment 5. Inactivated vaccines within 2 weeks prior to enrollment 6. Investigational research agents within 4 weeks prior to enrollment or planned to receive investigational products while on the study 7. Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule 8. Current anti-TB (tuberculosis) prophylaxis or therapy 9. Previous investigational H1 influenza vaccine 10. Previous investigational ferritin-based vaccine 11. Receipt of a licensed influenza vaccine within 6 weeks before trial enrollment Participant has a history of any of the following clinically significant conditions: 12. Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator 13. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema 14. Asthma that is not well controlled 15. Diabetes mellitus (type I or II), with the exception of gestational diabetes 16. Thyroid disease that is not well controlled 17. Idiopathic urticaria within the past year 18. Autoimmune disease or immunodeficiency 19. Hypertension that is not well controlled (baseline systolic \> 140 mmHg or diastolic \> 90 mmHg) 20. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws 21. Malignancy that is active or history of malignancy that is likely to recur during the period of the study. 22. Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years 23. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen 24. Guillain-Barré Syndrome 25. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a participant's ability to give informed consent.

Outcomes

Primary Outcomes

Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration

Participants recorded the occurrence of solicited symptoms on a diary card for 7 days after each study product administration and reviewed the diary card with clinic staff at a follow up visit. Participants were counted once for each symptom at the worst severity if they indicated experiencing the symptom more than one time at any severity during the reporting period. The number reported for "Any Local Symptom" is the number of participants reporting any local symptom at the worst severity. Reactogenicity grading (Mild, Moderate, Severe) was done using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, modified from FDA Guidance - September 2007.

Time frame: 7 days after each H1ssF_3928 product administration, at approximately Week 1 and at approximately Week 17

Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration

Participants recorded the occurrence of solicited symptoms on a diary card for 7 days after each study product administration and reviewed the diary card with clinic staff at a follow up visit. Participants were counted once for each symptom at the worst severity if they indicated experiencing the symptom more than one time at any severity during the reporting period. The number reported for "Any Systemic Symptom" is the number of participants reporting any systemic symptom at the worst severity. Reactogenicity grading (Mild, Moderate, Severe) was done using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, modified from FDA Guidance - September 2007.

Time frame: 7 days after each H1ssF_3928 product administration, at approximately Week 1 and at approximately Week 17

Number of Participants With One or More Unsolicited Non-Serious Adverse Events (AEs) Following H1ssF_3928 Product Administration

Unsolicited AEs and attribution assessments were recorded in the study database from receipt of the first study product administration through the visit scheduled for 4 weeks after each study product administration. At other time periods between study product administrations and when greater than 4 weeks after the last study product administration, only serious AEs (SAEs reported as a separate outcome and in the AE module), influenza-like illness (ILI) or influenza and new chronic medical conditions that required ongoing medical management (reported as separate outcomes) were recorded through the last study visit. The relationship between an AE and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol. A participant with multiple experiences of the same event is counted once using the event of worst severity.

Time frame: Day 0 through 4 weeks after each H1ssF_3928 product administration, up to Week 20

Number of Participants With Serious Adverse Events (SAEs) Following H1ssF_3928 Product Administration

SAEs were recorded from receipt of first study product administration through the last expected study visit at Week 68. The relationship between a SAE and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol. A participant with multiple experiences of the same event is counted once using the event of worst severity.

Time frame: Day 0 through the study participation, up to Week 68

Number of Participants With Influenza or Influenza-like Illness (ILIs) Following H1ssF_3928 Product Administration

Influenza or influenza-like illness (ILI) were recorded in the study database from receipt of the first study product administration through the last study visit.

Time frame: Day 0 through the study participation, up to Week 68

Number of Participants With New Chronic Medical Conditions Following H1ssF_3928 Product Administration

New chronic medical conditions that required ongoing medical management were recorded from receipt of first study product administration through the last expected study visit at Week 68. The relationship between a new chronic medical condition and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol. A participant with multiple experiences of the same event is counted once using the event of worst severity.

Time frame: Day 0 through the study participation, up to Week 68

Number of Participants With Abnormal Laboratory Measures of Safety Following H1ssF_3928 Product Administration

Any abnormal laboratory results recorded after product administration as unsolicited adverse events (AEs) are summarized. Safety laboratory parameters included hematology (hemoglobin, hematocrit, platelets, and white blood cell (WBC), red blood cell (RBC), neutrophil, lymphocyte, monocyte, eosinophil and basophil percents/counts) and chemistry (alanine aminotransferase (ALT), alanine aspartate (AST), alkaline phosphate (ALP), creatinine and total bilirubin). Complete blood count (CBC) with differential, total bilirubin, AST, ALT, and ALP results were collected at Days 14, 28, 280, 364 and 476. Iron and serum ferritin were collected at Day 28. Creatinine results were collected at Day 14. Institutional laboratory normal ranges as well as the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials FDA Guidance, September 2007 were used.

Time frame: Day 0 through the study participation, up to Week 68

Secondary Outcomes

Pseudoviral Neutralization Assay Geometric Mean Titer (GMT) Against Homologous A/New Caledonia/20/1999 Virus (H1N1) Following the Completion of Each Vaccination Regimen

Pseudoviral neutralization antibody titers were determined against the homologous H1N1 A/New Caledonia/20/99 virus, and were summarized using geometric mean 80% inhibitory concentration (IC80).

Time frame: Baseline to 2 weeks after 1st dose for participants who received a single injection, at Week 2 or From Baseline to 2 weeks after 1st dose and from Week 16 to 2 weeks after 2nd dose for participants who received two injections, at Weeks 2 and 18

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes